Poster Presentations

« Back Print this page

  Personalized Program
The Personalized Program enables you to compile an individual program with events and contributions of your interest. Therefore, it can be used very well to plan your actual congress visit at an early point of time. Please log in to use the Personalized Program.
 » Login
» Identification
» Help
   
  

Sunday, 28. June 2009

 next day » 
     
No. P-01 - Poster Presentation
Time: 12.30-14.00
Room: Foyer
Topic: Addictive Disorders
Session title: Addictive Disorders I
  Amine Benyamina, France Chair
     
001 Investigation of ventromedial prefrontal cortex associated decision-making skills at the beginning of abstinence in alcohol addicted patients  
  Bálint Andó, Hungary Presenter
002 Attentional bias associated with cocaine cues: Differences among cocaine dependents, occasional cocaine users and controls  
  Gabriel Rubio, Spain Presenter
003 Neurofeedback for treating substance use disorders: A review  
  Anja Neumann-Thiele, Germany Presenter
004 Experience of Gabapentin (Tebantin®) application for treatment of alcohol cancellation in intact condition  
  Aleksandr Kim, Kazakhstan Presenter
005 Inhibition of anandamide hydrolysis reduces reinstatement of nicotine seeking but not motivation for nicotine - Comparison with CB1 receptor blockade  
  Benoit Forget, Canada Presenter
007 Tobacco smoking and motivation to quit in psychiatric patients  
  Eva Gonçalves, Portugal Presenter
008 Cocaine induced psychotic symptoms in a French sample of cocaine addicts  
  Florence Vorspan, France Presenter
009 Assessment of denial and insight in patients with nicotine and alcohol dependence  
  Florence Vorspan, France Presenter
010 Adaptation of the MOPS (Measurement of Parental Styles) in French: Preliminary results in drug dependant outpatients  
  Florence Vorspan, France Presenter
011 Alcohol use end anxious depressive disorders  
  Alexandru Tiugan, Romania Presenter
012 Differential characteristics between substance - induced and primary psychotic disorders  
  Gerard Mateu Codina, Spain Presenter
013 A flow-cytometric and electron - microscopic study of the combined effect of human immunodeficiency virus (HIV)-1 Tat and methamphetamine on the human neuroblastoma cell line SH-SY5Y  
  Li Qi, China, People's Republic of : Presenter
014 Drug addiction among schizophrenic inpatients  
  Radhouene Kachouri, Tunisia Presenter
015 Personality characters as a predictor of tendency to addiction  
  Gholam Ali Nikpour, Iran Presenter
016 The role of the relationship between therapist and patient in an individual outpatient program for drug addiction treatment by the administration of naltrexone  
  Lygeri Iliopoulou, Greece Presenter
017 Effects of microwave resonance therapy on oxidative modification of proteins and lipids of blood plasma and erythrocyte in alcoholism  
  Valentina Prokopyeva, Russia Presenter
018 Factors associated with relapse of drug addiction among males in Selangor, Malaysia  
  Mas Ayu Said, Malaysia Presenter
019 Event-related potential subsequent memory effect dysfunction in chronic cannabis users  
  Robert Battisti, Australia Presenter
020 Visuospatial memory deficits, subclinical psychotic symptoms and structural brain changes in long term heavy cannabis users  
  Robert Battisti, Australia Presenter
021 The effect of 3,4-Methylendioxymetamphetamine (MDMA) on proliferation and survival of neurons in hippocampus in adult rats  
  Martina Kutová, Czech Republic Presenter
     
No. P-02 - Poster Presentation
Time: 12.30-14.00
Room: Foyer
Topic: Affective Disorders (Unipolar)
Session title: Affective Disorders (Unipolar) I
  Rajesh Nagpal, India Chair
     
001 Executive control of emotion in depression  
  Melissa Green, Australia Presenter
002 Selective response of dopamine in the presence of ascorbic acid at carbon nanotubes paste modified electrode  
  Adela Ciobanu, Romania Presenter
003 An association between physical activities and depression in working population  
  Dalia Stropute, Lithuania Presenter
004 The increase in Serotonin Transporter occupancy from single to multiple dosing is associated with treatment outcome in major depressive disorder  
  Elena Akimova, Austria Presenter
007 Modafinil reduces microsleep during partial sleep deprivation and improves antidepressant treatment response  
  Johannes Beck, Switzerland Presenter
008 No predictors of antidepressant response to Milnacipran was obtained using the Three Factor Structures of the Montgomery and Åsberg Depression Rating Scale in Japanese patients with major depressive disorders  
  Hisashi Higuchi, Japan Presenter
009 Predictors of antidepressant response to Fluvoxamine Obtained using the Three-Factor Structures of the Montgomery and Åsberg Depression Rating Scale for major depressive disorders in Japanese patients  
  Hisashi Higuchi, Japan Presenter
010 Neuropsychological impairment and high prevalence of depression in patients with chronic Hepatitis C virus  
  Signe Groth Renvillard, Denmark Presenter
011 Depression severity: Is it influenced by chronotypes?  
  Enrique Gaspar, Mexico Presenter
012 Administration of cannabinoid CB2 receptor antagonist AM630 decreased emotional-like behaviours after acute and chronic depressive stimuli  
  Jorge Manzanares, Spain Presenter
013 Overexpression of cannabinoid CB2 receptors results in decreased response to acute and chronic depressive stimuli  
  Jorge Manzanares, Spain Presenter
014 A specific memory profile in depression remitters following electroconvulsive therapy: Preliminary findings  
  Maria Semkovska, Ireland Presenter
015 Prevalence of perinatal depression in Portuguese women preliminary results  
  Ana Telma Pereira, Portugal Presenter
016 Efficacy and Safety of Desvenlafaxine 50 and 100 mg/d in the Treatment of Major Depressive Disorder: Results From 2 Placebo-Controlled Studies  
  Karen Tourian, France Presenter
017 Analysing depression using DASS-21 scale among diabetes in Malaysia  
  Salmiah Mohd Ali, Malaysia Presenter
018 Depression and rheumatoid arthritis - case report  
  Nebojsa Ilic, Serbia and Montenegro Presenter
019 The study of the relationship between depression and trust in god among undergraudate students  
  Mohammad Mehdi Naderi, Iran Presenter
020 Revealing of psychological problems at women  
  Irina Bitchenko, Ukraine Presenter
     
No. P-03 - Poster Presentation
Time: 12.30-14.00
Room: Foyer
Topic: Anxiety
Session title: Anxiety I
  Sabine Herpertz, Germany Chair
     
001 Sustained attention on Bosnian war veterans with PTSD diagnosis  
  Aida Sarac-Hadzihalilovic, Bosnia and Herzegovina Presenter
002 Salivary cortisol and emotional arousal in Bosnian refugees with PTSD  
  Aida Spahic-Mihajlovic, USA Presenter
003 Application of ASEX-scale for patients with posttraumatic stress disorder by telepsychiatry and psychiatry  
  Milan Stojakovic, Bosnia and Herzegovina Presenter
004 The model of prediction of neurotic, stress-related and somatoform disorders  
  Lyudmila Ryadovaya, Russia Presenter
005 Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with Generalised Anxiety Disorder (GAD)  
  Kairi Mägi, Estonia Presenter
006 Pharmacology of neuropeptides in a mouse model of extremes in anxiety-related behavior  
  Yi-Chun Yen, Germany Presenter
007 Improvement of cognitive functions in anxiety patients treated with psychotherapy and pharmacotherapy  
  Krzysztof Krysta, Poland Presenter
008 Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy for the acute treatment of patients with Generalised Anxiety Disorder (GAD): An analysis of pooled data  
  Borwin Bandelow, Germany Presenter
009 Frequency and clinical correlates of adult separation anxiety disorder in a sample of 508 outpatients with mood and anxiety disorders  
  Marianna Abelli, Italy Presenter
010 Morphological analyses of neurons in serotonin transporter knockout mice  
  Sarah Louise Nietzer, Germany Presenter
011 Efficacy of alprazolam sub-lingual tablets in the acute phase of panic disorders  
  Miguel Márquez, Argentina Presenter
012 Executive and metacognitive deficit in the social anxiety disorders  
  Miguel Márquez, Argentina Presenter
013 Generalized anxiety disorder: The neuropsychological approach  
  Miguel Márquez, Argentina Presenter
014 Increased anxiety-like behaviours and impaired anxiolytic response to benzodiazepines in prodynorphin knock out mice is assoctiated to alterations in Gaba a receptor subunits gene expression and MAPK signaling pathway  
  Jorge Manzanares, Spain Presenter
015 Subtypes not respiratory of panic disorders and their correlation with fear of physical activity  
  Ricardo Muotri, Brazil Presenter
016 Quetiapine monotherapy in the treatment of posttraumatic stress disorder: A randomized, controlled trial  
  Mark Hamner, USA Presenter
017 Agoraphobia-leading women syndrom  
  Tatijana Kozarov, Serbia and Montenegro Presenter
018 Posttraumatic Stress Disorder (PTSD) and psychotic symptoms  
  Narcisa Pojskic, Bosnia and Herzegovina Presenter
019 Korean medication algorithm project for generalized anxiety disorder 2009: Initial treatment strategies  
  Min-Sook Kim, Korea, Republic of Presenter
020 Proinflammatory cytokine and HPA-axis responses to the combined dex/CRH test in remitted subjects with posttraumatic stress disorder and trauma controls  
  Nicole Szesny, Germany Presenter
     
No. P-04 - Poster Presentation
Time: 12.30-14.00
Room: Foyer
Topic: Childhood Adolescent Disorder
Session title: Childhood & Adolescent Disorders I
  Nobumasa Kato, Japan Chair
     
001 Epidemiology of PANDAS in children with and without comorbidity of streptococcal ethiology  
  Alina Matynova, Russia Presenter
002 Pattern of psychopharmacological treatment in pediatric bipolar disorders: Comparison between preschool-onset and school-age-onset outpatients  
  Ana Paula Ferreira Maia, Brazil Presenter
003 No effect of x-inactivation on twin discordance in IQ and behavioral problems at middle childhood  
  Bart Rutten, Netherlands Presenter
004 Mental pathology in parents of children suffering from psychosomatic disorders  
  Anatoly Severny, Russia Presenter
005 Methylphenidate alteration of neurotransmitters and synaptic parameters in PC12 cells  
  Edna Grünblatt, Germany Presenter
006 Social and behavioral characteristics of children with Rubinstein-Taybi Syndrome  
  Cedric Galera, France Presenter
007 Pilot study to correlate circulating Cytokine and Cortisol levels in South African children presenting acutely to a sexual abuse clinic  
  Dee Muller, South Africa Presenter
008 Issues of behavioral problems among adolesents of Georghian schools  
  Marine Gegelashvili, Georgia Presenter
009 Psychiatric outcome of paediatric epilepsy surgery  
  Tai Sum Tony Lai, China, People's Republic of Presenter
010 Short- , intermediate- , and long-acting stimulant treatment patterns in patients with attention-deficit hyperactivity disorder (ADHD)  
  Paul Hodgkins, USA Presenter
011 Stimulant and atomoxetine treatment patterns in patients with attention-deficit hyperactivity disorder  
  Paul Hodgkins, USA Presenter
012 Memory processes of adolescent with intellectual disabilities and hearing impairments  
  Jasmina Kovacevic, Serbia and Montenegro Presenter
013 Biological predictors of re-incarceration in mentally ill young offenders  
  John Kasinathan, Australia Presenter
014 The fatherless brain: Impact of paternal deprivation in Peromyscus californicus on social behaviour and on Oxytocin, NMDA and monaminergic synapses in the prefrontal cortex  
  Francis Bambico, Canada Presenter
015 Correlation between variants of the DRD4 gene and intra-individual variability of behavior in Attentional Deficit/Hyperactivity Disorder (ADHD)  
  Marcela Henríquez, Chile Presenter
016 Effects of a single bout of intense physical exercise on working memory functions in adult attention deficit/ hyperactivity disorder  
  Bernward Winter, Germany Presenter
017 Sensory abnormality profiles in adults with developmental disorders: Autism spectrum disorder (ASD) versus attention deficit and hyperactivity/impulsivity disorder (ADHD): Usefulness in diagnosis and treatment implications  
  Wim Verbeeck, Belgium Presenter
018 Psychiatric comorbidity in adults with Autism Spectrum Disorder  
  Wim Verbeeck, Belgium Presenter
     
No. P-05 - Poster Presentation
Time: 12.30-14.00
Room: Foyer
Topic: Neurodegenerative Disorders
Session title: Neurodegenerative Disorders I
  Alexandre Dailliet, Belgium Chair
     
001 Regular moderate physical exercise improves mood and quality of life in older patients with atrial fibrillation  
  Christine Norra, Germany Presenter
002 EEG complexity in Alzheimer’s disease: Multiscale entropy analysis  
  Tomoyuki Mizuno, Japan Presenter
003 Rivastigmine and behavioral disorder of the patients in the centers for old persons  
  Aleksandar Miljatovic, Serbia and Montenegro Presenter
004 Cerebrolysin in the treatment of dementia mixed type and Alzheimer’s disease  
  Andreea Silvana Szalontay, Romania Presenter
005 Safety, efficacy, and biomarker findings of PBT2 in targeting ?-amyloid as a modifying therapy for Alzheimer's disease: A phase IIa, double-blind, randomised, placebo-controlled trial  
  Olivia Dean, Australia Presenter
006 The implication of oxidative stress in a rat model of Parkinson's disease  
  Ciobica Alin, Romania Presenter
008 Crime or illness? The mystery of Frontotemporal Dementias  
  Franziskos Xepapadakos, Switzerland Presenter
009 Donepezil reverses beta-amyloid-induced deficits in long term potentiation in rat hippocampal slices  
  Elena Solntseva, Russia Presenter
010 Benefit of analyzing biological markers in cerebrospinal fluid in diagnosing Alzheimer’s during a consultation with an expert from a Centre Mémoire de Ressources et de Recherche  
  Danièle Bentué-Ferrer, France Presenter
011 Effects of apolipoprotein E genotype on behavioral and psychological symptoms in Alzheimer’s disease  
  Shin-Gyeom Kim, Korea, Republic of Presenter
013 Examining gene-gene interactions between tau haplotypes and ApoE4 in Alzheimer’s disease  
  Péter Álmos, Hungary Presenter
014 Creutzfeldt-Jakob dementia and psychiatric symptoms  
  José de Santiago Sastre, Spain Presenter
015 Symptomatic treatment of delirium  
  José de Santiago Sastre, Spain Presenter
016 Classifying what? How dementia classifications shape the concept of “normal” aging  
  Lara Katharina Kutschenko, Germany Presenter
017 Inflammatory biomarkers in Alheimer’s Disease: Clinical correlates  
  Anton Alvarez, Spain Presenter
018 Dementia caused by Sanfilippo B syndrome  
  Willem Verhoeven, Netherlands Presenter
019 Pharmacotherapy in intellectual disabilities  
  Willem Verhoeven, Netherlands Presenter
020 White matter lesions in Korsakoff syndrome  
  Willem Verhoeven, Netherlands Presenter
     
No. P-06 - Poster Presentation
Time: 12.30-14.00
Room: Foyer
Topic: Psychotic Disorders
Session title: Psychotic Disorders I
  Rainer Rupprecht, Germany Chair
     
001 Compliance therapeutic adhesion over 8 year of follow-up in first psychotic episodes  
  Sara Barbeito, Spain Presenter
002 Impact of methamphetamine use in first episode psychosis  
  Bonginkosi Chiliza, South Africa Presenter
003 Greek translation and reliability of the Psychotic Symptom Rating Scales (PSYRATS)  
  Costas Kollias, Greece Presenter
004 Heart rate variability and Antrieb (drive, impulse) in catatonic schizophrenias - affection of the autonomic nervous system as a possible link between neurophysiological and psychopathological variables  
  Felix Hohl-Radke, Germany Presenter
005 Two days treatment of auditory hallucinations by high frequency rTMS guided by cerebral imaging: A 6 months follow - up study  
  Aurelie Montagne-Larmurier, France Presenter
006 Glutathione redox system and lipid peroxidation in patients with schizophrenia  
  Anastasia Ivanova, Russia Presenter
007 'Theory of mind’ in ultra high risk and first episode psychosis cohorts: Preliminary findings on degree of impairment  
  Cali Bartholomeusz, Australia Presenter
008 Risperidon, right choice of treatment for schizophrenia? Experience obtained through practice  
  Aleksandar Macic, Serbia and Montenegro Presenter
009 Abnormalities in the spontaneous and steady-state EEG activity of schizophrenics  
  Fabio Ferrarelli, USA Presenter
010 Effects of Selegiline on negative symptoms in schizophrenia: A double-blind, placebo-controlled, study  
  Ebrahim Abdollahian, Iran Presenter
011 The schizophrenia silent shout: The apathy  
  Daniel Dachesky, Argentina Presenter
012 Deficits in the inhibition of Gamma Oscillations in the Dorsolateral Prefrontal Cortex of patients with schizophrenia compared with Bipolar Disorder and healthy controls  
  Faranak Farzan, Canada Presenter
013 Implication of cryoglobulins in term of schizophrenia-associated immune system alterations  
  Aren Khoyetsyan, Armenia Presenter
014 Recognition of positive and negative emotions in schizophrenic patients: A experimental paradigm with faces  
  Francisco Pizarro, Chile Presenter
015 Atypical side effects of Antipsychotics - risk factor for noncompliance in first episode of schizophrenia  
  Gabriela Grigorescu, Romania Presenter
016 Cognitive impairment profile in schizophrenia  
  Gabriela Grigorescu, Romania Presenter
017 Efficacy of aripiprazole vs quetiapine for the treatment of hostility in acute patients with schizophrenia  
  Gabriela Grigorescu, Romania Presenter
018 Parametric variation in working memory demand in patients with schizophrenia: A behavioral and neuroimaging pilot study  
  Jared Van Snellenberg, USA Presenter
019 Disturbance of metacognition of agency in patients with schizophrenia  
  Jared Van Snellenberg, USA Presenter
     
No. P-07 - Poster Presentation
Time: 12.30-14.00
Room: Foyer
Topic: Psychotic Disorders
Session title: Psychotic Disorders II
  Pichet Udomratn, Thailand Chair
     
001 Epileptic psychosis: A report of three cases  
  Cristina Gonzalez Mingot, Spain Presenter
002 Enhanced cortisol suppression in response to dexamethasone administration in first episode psychosis patients  
  Christina Phassouliotis, Australia Presenter
003 Inflammatory component in pathogenesis of schizophrenia and post-traumatic stress disorder  
  Anna Boyajyan, Armenia Presenter
004 Circadian melatonin rhythm in paranoid schizophrenic patients  
  Estefania Diaz Mesa, Spain Presenter
005 Do patients with auditory hallucinations have auditory processing deficits?  
  Dougal Phillips, Australia Presenter
006 Environmental Supports Improve Negative Symptoms in Schizophrenia  
  Natalie Maples, USA Presenter
007 Reduced early auditory evoked gamma band response in patients with schizophrenia  
  Gregor Leicht, Germany Presenter
008 Autoimmunity in bipolar and schizophrenic disorders  
  Maria Isabel Ganhao Rodrigues, Portugal Presenter
009 Single trial P3a/P3b deficits discriminate cognitive deficits in borderline personality disorder from schizophrenia  
  Kerri Brown, Australia Presenter
010 Electroconvulsive Therapy (ECT) in schizophrenia associated with violence: A case series  
  Mrigendra Das, United Kingdom Presenter
011 Latency classification of the frontal MMN responses to the pitch deviants in schizophrenic patients  
  Josef Zislin, Israel Presenter
012 Efficacy of haloperidol and quetiapine combination in refractory schizophrenia: A case report  
  Michalis Saitis, Greece Presenter
013 Gamma-interferon and interleukin-4 levels in the process of treatment of schizophrenic patients  
  Olga Lobacheva, Russia Presenter
014 Substance use disorder comorbidity in Latinos with schizophrenia  
  Lorena Jimenez Castro, USA Presenter
015 New-onset psychosis associated with HIV infection treated with HIV antiretroviral medications and inclusion of HIV medication in involuntary mental health treatment  
  Melissa Corr, Australia Presenter
016 The effect of cigarette smoking on prepulse inhibition and P50 suppression in Japanese patients with schizophrenia  
  Kazumichi Hashimoto, Japan Presenter
017 Influence of infections on schizophrenic patients  
  Daniela Friebel, Germany Presenter
018 Types of transaction in the family as they are expressed in space arrangements and the habits in the house with schizophrenic  
  Nikolaos Marketos, Greece Presenter
019 Antineuronal Antibodies in a schizophrenic patient and his family  
  Konstantinos Kylintireas, Greece Presenter
     
No. P-08 - Poster Presentation
Time: 12.30-14.00
Room: Foyer
Topic: Brain Function
Session title: Brain Function I
  Gerhard Gründer, Germany Chair
     
001 Pharmacological characterization of the rhesus macaque Nociceptin receptor  
  Christophe Grundschober, Switzerland Presenter
002 Possible role of FK-506 against 3-nitropropionic acid induced behavioral, biochemical, mitochondrial and neurochemical changes in striatum, cortex and hippocampus of rat brain  
  Puneet Kumar Bansal, India Presenter
003 The role of nitric oxide system in the anticonvulsant effect of the cannabinoid CB1 agonist ACEA in the pentylenetetrazole-induced seizure in mice  
  Arash Bahremand, Iran Presenter
005 [3H]-YM-09151-2 binding sites in human brain postmortem  
  Donatella Marazziti, Italy Presenter
006 A relationship between Brain-Derived Neurotrophic Factor and romantic attachment  
  Donatella Marazziti, Italy Presenter
007 Men axillary extracts modify the affinity of the platelet serotonin transporter and impulsiveness in women  
  Donatella Marazziti, Italy Presenter
008 Study of influence Agonists and Antagonists of Dopaminergic Receptors on morphine-induced analgesia and tolerance  
  Elene Abzianidze, Georgia Presenter
009 Uncoupling the D1-NMDA receptor complex Promotes NMDA-dependent LTP and working memory  
  Fang Liu, Canada Presenter
010 Phospholipids in dynamics of free radical oxidation of lipids in biological membranes brain under conditions of Parkinson’s disease  
  Gayane Ghazaryan, Armenia Presenter
011 Sarcosine reversed the MK-801-induced disruption of spontaneous alternation behavior in mice  
  Shinji Takahashi, Japan Presenter
012 Effect of sytemic administration of CH 113 on cognitive functions after excitotoxic hippocampus lesions in spatial learning task  
  Lukas Rambousek, Czech Republic Presenter
013 Limbic system surgery for the treatment of obsessive compulsive disorders  
  Delcyr Antônio Costa, Brazil Presenter
014 Involvement of 5-HT2B receptors in the regulation of energy homeostasis  
  Sophie Banas, France Presenter
015 First characterization of tryptophan hydroxylase 2 knockout mice  
  Jonas Waider, Germany Presenter
016 Possible Roles of BDNF - induced Microglial Intracellular Ca 2+ Elevation in the pathophysiology of psychiatric disorders  
  Yoshito Mizoguchi, Japan Presenter
017 Central effects of antidiuretic peptide desmopressin after its peripheral application on spontaneous behavior of rats  
  Vera Klenerova, Czech Republic Presenter
018 Renalase, a novel monoamine oxidase, is synthesised in the central nervous system  
  Sarah Hennebry, Australia Presenter
019 Is tyramine hydroxylation to dopamine operative in the brain?  
  Anna Haduch, Poland Presenter
     
No. P-09 - Poster Presentation
Time: 12.30-14.00
Room: Foyer
Topic: Genetics
Session title: Genetics I
  Min-Soo Lee, Korea, Republic of Chair
     
001 Cis-acting regulatory influences on the schizophrenia candidate gene RGS4 in human brain  
  Federica Buonocore, United Kingdom Presenter
002 Maltreatment, MAOA, and delinquency: Sex differences in gene-environment interaction in a large population-based cohort of adolescents  
  Kent Nilsson, Sweden Presenter
003 BDNF gene polymorphisms and susceptibility to schizophrenia in the Cluj schizophrenic population of Romania  
  Ali Sazci, Turkey Presenter
004 Is the MTHFR A1298C and COMT val158met polymorphisms associated with schizophrenia in the Cluj Napoca population of schizophrenics in Romania?  
  Emel Ergul, Turkey Presenter
005 Methylenetetrahydrofolate reductase gene polymorphisms and susceptibility to schizophrenia in the city of Cluj Napoca in Romania  
  Emel Ergul, Turkey Presenter
006 The role of gene-gene and gene-environment interactions in individual variations of personality traits  
  Anastasiya Kazantseva, Russia Presenter
008 Association between infant irritability, 5-HTT and a putative functional polymorhpism located in TFAP2B  
  Jose Luis Ivorra, Spain Presenter
009 Genetic interaction of alpha-7 nicotinic acetylcholine receptor and brain-derived neurotrophic factor polymorphisms in Alzheimer’s disease  
  Agnes Fehér, Hungary Presenter
010 Detection of stable reference genes for real-time PCR analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder  
  Ruth Navon, Israel Presenter
011 Polymorphisms in the GABRA6 gene influence coping style in healthy adults and show evidence for a gene-environment interaction with life events  
  Angela Heck, Germany Presenter
012 Association among aggressiveness, neurocognitive function, and the Val66Met polymorphism of brain-derived neurotrophic factor (BDNF) gene in male schizophrenic patients  
  Hyo-Jung Ko, Korea, Republic of Presenter
013 SMAD4 gene is associated with psychosis in the Cost Rican population  
  Ivan Chavarria-Siles, USA Presenter
014 Multifactor dimensionality reduction reveals gene - gene interactions associated with Antisocial Personality Disorder in Colombia  
  Jorge Mauricio Cuartas Arias, Colombia Presenter
015 Chromosomial abnormalities in some cases with schizophrenia  
  Emilia Burada, Romania Presenter
016 Genetic association study with dysbindin gene: Common genetic factors for schizophrenia and bipolar disorders?  
  Aida Ruiz, Chile Presenter
017 Ethnic difference in pharmacogenetic result in major depression: The result of meta-analysis  
  Masaki Kato, Japan Presenter
018 5-HT1A gene polymorphisms contributed to antidepressant response in major depressive disorder  
  Masaki Kato, Japan Presenter
019 Escitalopram modulates the panic response to choleystokinin tetrapeptide in healthy men depending on 5-HTTLPR genotype  
  Michael Kellner, Germany Presenter
020 The defence mechanism in biology  
  Enrico Venga, Italy Presenter
     
No. P-10 - Poster Presentation
Time: 12.30-14.00
Room: Foyer
Topic: Psychopharmacology
Session title: Psychopharmacology/Antidepressants
  Thomas Raedler, Canada Chair
     
001 Corticotropin - releasing factor receptor 1 antagonist attenuates neurochemical responses against swim stress in the rodent brain  
  Ayako Ohashi, Japan Presenter
002 Treatments patterns, resource use and related healthcare costs in depressed patients with co-morbid anxiety in a large US claims database  
  Florent Guelfucci, France Presenter
003 Induction of violence by psychotropic drugs: Signal detection  
  David Menkes, New Zealand Presenter
004 Violence as a side - effect of antidepressants: Provocation by alcohol  
  David Menkes, New Zealand Presenter
005 Antidepressants for prevention of interferon-alpha-induced depression: A meta-analysis  
  Bruno Fábregas, Brazil Presenter
006 Antidepressants post-receptor mechanism of action involves beta-arrestins and extracellular signal-regulated kinases  
  Moran Golan, Israel Presenter
007 A case of neuroleptic malignant syndrome induced by atypical antipsychotics  
  Feryal Cam Celikel, Turkey Presenter
008 Venlafaxine-associated manic episode in a young depressive patient  
  Feryal Cam Celikel, Turkey Presenter
009 Antidepressants inhibit microglial activation: The possibility of a novel therapeutic effect  
  Hideki Horikawa, Japan Presenter
010 Effect of antidepressant therapy on brain neurotrophic factors, brain ERK system and cognitive performance of rats exposed to chronic mild stress  
  Abraham Weizman, Israel Presenter
011 The 5-HT2B receptor is necessary for the behavioral and neurogenic effects induced by chronic SSRI treatment  
  Silvina Laura Diaz, France Presenter
012 Peripheral biomarkers are modulated by early-life stress and antidepressant treatment in a gene-environment interaction model of depressive disorder in rats  
  Lucia Carboni, Italy Presenter
013 The TREK-1 potassium channel as a new antidepressant target  
  Marc Borsotto, France Presenter
014 The efficacy of Desvenlafaxine 50 mg/d for improving anxiety symptoms in patients with major depressive disorder: A pooled analysis  
  Karen Tourian, France Presenter
015 Antidepressant psychotropic/ psychological effects in healthy subjects  
  Alessandro Serretti, Italy Presenter
016 Effect of the p38 MAP kinase inhibitor SB-239063 on behaviour and peripheral biomarkers in the Lipopolysaccharide (LPS) induced sickness model in rats  
  Silvia Bison, Italy Presenter
017 The involvement of GABAA receptor in the molecular mechanism of combined antidepressant and antipsychotic treatment  
  Lena Danovich, Israel Presenter
018 A slow vs standard up-titration with Paroxetine in the treatment of panic disorder  
  Bernardo Dell’Osso, Italy Presenter
019 Effects of commercially available products of St John’s Worth in Serbia on forced swimming and tail suspension tests in mice  
  Vladimir Janjic, Serbia and Montenegro Presenter
020 Escitalopram as monotherapy in major Depressive Disorder with insomnia  
  Vladimir Janjic, Serbia and Montenegro Presenter
     
No. P-11 - Poster Presentation
Time: 12.30-14.00
Room: Foyer
Topic: Other
Session title: Other/Eating Disorders
  Michel Dierick, Belgium Chair
     
001 Treating binge eating disorder and substance use problems effectively with mindfulness based cognitive behavioral group therapy  
  Christine Courbasson, Canada Presenter
002 Eating disorders - types of obsessive-compulsive disorder  
  Dragana Krasic, Serbia and Montenegro Presenter
003 Psychiatric comorbidities and childhood personality traits associated with subthreshold eating disorders in a population-based longitudinal study of adolescent girls  
  Evelyne Touchette, France Presenter
004 Body image in adolescent boys and girls: A 4-year longitudinal study  
  Marie-Eve Blackburn, Canada Presenter
005 Translation of the SCOFF questionnaire and validation of this French version for the screening of eating disorders in a student population  
  Frederico Duarte Garcia, France Presenter
006 Using EAT to identify risk factors for Eating Disorders in a sample of Brazilian students  
  João Eduardo M. Vilela, Brazil Presenter
007 Eating behavior: The role of family configuration  
  Tatiana Meshkova, Russia Presenter
008 Cancer-related anorexia treatment program and quality of life in cancer patients  
  Vyacheslav Sushko, Ukraine Presenter
009 Nutritional state related to the corporal mass index in patients admitted to a psychiatric hospital with mental and behavioral disorders in Mexico City  
  Carlos Castañeda, Mexico Presenter
010 Methabolic syndrome prevalence in patients admitted to Fray Bernardino Alvarez Psychiatric Hospital  
  Lina Diaz Castro, Mexico Presenter
011 Sleep quality and quality of life in multiple sclerosis  
  Usha Barahmand, Iran Presenter
012 Prevalence of obsessive beliefs and intolerance of uncertainty among college students  
  Usha Barahmand, Iran Presenter
013 Electro-acupuncture diagnostic method for assessing of adjustment disorders in breast cancer patients  
  Vyacheslav Sushko, Ukraine Presenter
014 Cognitive functioning, emotional state and quality of life in prediabetic persons  
  Lina Lasaite, Lithuania Presenter
015 Neurosarcoidosis psychiatric disorder  
  Abderrazzak Ouanass, Morocco Presenter
016 Body dysmorphic disorder: Case report, relations with physical illness and diagnostic categorization  
  Jaime Pedroso Almeida, Portugal Presenter
017 Body dysmorphic disorder and its psychological correlates  
  Usha Barahmand, Iran Presenter
018 Cryoglobulinemy revealed by insanity syndrome  
  Abderrazzak Ouanass, Morocco Presenter
019 Aripiprazole - Anorexia  
  François Granier, France Presenter
020 A survey study of the social abnormality among the university students  
  Ahmad Bayan Memar, Iran Presenter
021 Studying the relationship between emotional intelligence and principals' performance  
  Ahmad Bayan Memar, Iran Presenter
022 The psychology of job stress from legend to reality  
  Ahmad Bayan Memar, Iran Presenter
 
 

Sunday, 28. June 2009

 next day »
  « Back